ライフサイエンスコーパス: oncogenic protein

1 eal other novel activities of this important oncogenic protein.

2 d, thus, AMF/PGI represents a novel class of oncogenic protein.

3 y to the BCR or the ABL parts of the BCR-ABL oncogenic protein.

4 kinase (P13-K) was recently identified as an oncogenic protein.

5 necessitating new approaches to inhibit this oncogenic protein.

6 polyadenylation (pPA) of RNA can produce an oncogenic protein.

7 l-1, a Bcl-2 family protein, functions as an oncogenic protein.

8 t least one case leading to expression of an oncogenic protein.

9 lity to induce the breakdown of a variety of oncogenic proteins.

10 Ls), CD44 homing receptor, and p53 and Bcl-2 oncogenic proteins.

11 ith sequence similarity to developmental and oncogenic proteins.

12 specifically regulate the function of these oncogenic proteins.

13 to serum of EV containing some similar human oncogenic proteins.

14 und in several receptor tyrosine kinases and oncogenic proteins.

15 KA) and Rearranged during Transfection (RET) oncogenic proteins.

16 68 controls the alternative splicing of many oncogenic proteins.

17 A translation and the expression of specific oncogenic proteins.

18 nd activation of its clients, including many oncogenic proteins.

19 iciently silenced the drug exporters and the oncogenic proteins.

20 gle variable domains binding to RAS and LMO2 oncogenic proteins.

21 al stability, thus enhanced binding to the 2 oncogenic proteins.

22 , stabilization/degradation, and function of oncogenic proteins.

23 anslation of mRNAs, including those encoding oncogenic proteins.

24 imultaneously, such as the overexpression of oncogenic proteins, aberrant metabolite uptake and anoma

25 AXIN1-295aa functions as an oncogenic protein, activating the Wnt signaling pathway

26 lular vesicles (EV) secretion as carriers of oncogenic protein and their involvement in obesity-media

27 bit a characteristic profile of depletion of oncogenic proteins and concomitant elevation of Hsp72.

28 tringent regulation by tumor suppressors and oncogenic proteins and enhanced RNA pol III transcriptio

29 68 controls the alternative splicing of many oncogenic proteins and its role is modulated by post-tra

30 90 inhibitors simultaneously target multiple oncogenic proteins and provide an advantage for cancer t

31 USP21 determines the stability of oncogenic proteins and therefore is implicated in carcin

32 cluding 5 S rRNAs and tRNAs, is regulated by oncogenic proteins and tumor suppressors.

33 Many oncogenic proteins are more dependent on Hsp90 in mainta

34 Though functional gene fusions encoding oncogenic proteins are the most dramatic outcomes of gen

35 Novel inhibitors, targeting dysregulated oncogenic proteins, are being explored at pace.

36 dies to develop the detection of immunity to oncogenic proteins as tumor markers, as well as the deve

37 isplayed Tn3 libraries against two different oncogenic proteins associated with B-cell lymphomas, muc

38 ole in the folding and maturation of several oncogenic proteins, associates with Tcl1 protein and sta

39 ole in the folding and maturation of several oncogenic proteins, associates with WT1 protein and stab

40 The oncogenic protein Bcl-2 functions as a potent inhibitor

41 bilizing the mRNA encoding the pro-survival "oncogenic" protein, BCL-2, in B-cell lymphoma.

42 poptosis and mediates the degradation of the oncogenic protein BCL6.

43 presents a novel activating mechanism of the oncogenic protein beta-catenin that could contribute to

44 dicate that LRP6 may function as a potential oncogenic protein by modulating Wnt/beta-catenin signali

45 ate production of unwanted proteins, such as oncogenic proteins, by blocking the function of their mR

46 The 120-kDa proto-oncogenic protein c-Cbl is a multidomain adaptor protein

47 SS) that translocates a pro-inflammatory and oncogenic protein, CagA, into epithelial cells.

48 ess protein kinase Cepsilon (PKCepsilon), an oncogenic protein capable of promoting autocrine cell-si

49 cancer evolution by specifically regulating oncogenic proteins closely related to malignant transfor

50 s induced by many receptor and intracellular oncogenic proteins commonly activated in cancer, renderi

51 cells in vitro revealed higher abundance of oncogenic proteins compared to EV released by normal hum

52 iophysical characterization of, gankyrin, an oncogenic protein composed of seven ARs and six T/SxxH t

53 Moreover, it is apparent that oncogenic proteins comprise complex signaling networks t

54 tegies to therapeutically target homodimeric oncogenic proteins considered undruggable.

55 CKIs), and CDH1, and upregulation of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (

56 BM-MSC-derived exosomes had higher levels of oncogenic proteins, cytokines, and adhesion molecules co

57 cancer cells (i.e., increased expression of oncogenic proteins, decreased expression of tumor suppre

58 Among the oncogenic proteins dephosphorylated by PP2A, the MYC onc

59 Oncogenic proteins derived from tumor-associated HPV ind

60 t future studies targeting the "undruggable" oncogenic protein dimers.

61 Oncogenic protein dosage is tightly regulated to enable

62 urvival and sustained expression of multiple oncogenic proteins downstream of CypB may thus contribut

63 in tumor cells are mutated or overexpressed oncogenic proteins driving cancer cell growth, leading t

64 on anoscopy, we measured responses to HPV-16 oncogenic proteins E6 and E7, using the CD25/CD134 assay

65 4EGI-1 inhibits cellular expression of oncogenic proteins encoded by weak mRNAs, exhibits activ

66 lastoma pathogenesis downstream of the major oncogenic protein epidermal growth factor receptor varia

67 es have suggested that overexpression of the oncogenic protein epithelial membrane protein-2 (EMP2) c

68 sion of EV-regulated proteins and decreasing oncogenic protein expression levels.

69 erpinning obesity-mediated EV secretion with oncogenic protein expression, shedding light on their ro

70 The LIM-domain protein LMO2 is a T-cell oncogenic protein first recognized by gene activation th

71 ith a Fli-1 expression vector shows that the oncogenic protein Fli-1 can transactivate the GPIX promo

72 Galectin-3 is a multifunctional oncogenic protein found in the nucleus and cytoplasm and

73 proteins, and inhibition of DUBs that rescue oncogenic proteins from proteasomal degradation is of em

74 ancer cell death is inevitable after loss of oncogenic protein function.

75 ss granules (SGs), which are modulated by an oncogenic protein G3BP2.

76 The newly discovered oncogenic protein gankyrin, which contains six ankyrin r

77 Inhibiting the RAS oncogenic protein has largely been through targeting the

78 velopment of targeted therapies against such oncogenic proteins has imparted clinical benefit.

79 HER-2/neu, an overexpressed oncogenic protein, has been proposed as a human cancer v

80 Hsp90, crucial for the stability of numerous oncogenic proteins, has emerged as a promising therapeut

81 uppressor molecules and impaired disposal of oncogenic proteins have been linked to tumorigenesis.

82 Human immune responses to oncogenic proteins have been reported and are continuing

83 Immune system based treatments targeting oncogenic proteins have shown therapeutic efficacy in an

84 Over the past decade, RAS oncogenic proteins have transitioned from being deemed u

85 growth-inhibitory humanized Ab targeting the oncogenic protein HER-2/neu.

86 consistent with their ability to degrade the oncogenic protein, Her2.

87 The oncogenic protein HOXA9 plays a critical role in leukemi

88 r HRAS genes are mutated to encode an active oncogenic protein in a quarter of human cancers.

89 hese findings suggest that Rad may act as an oncogenic protein in breast tissues and demonstrate a po

90 JCV DNA sequence and expression of the viral oncogenic protein in human brain tumors.

91 ere is no reported involvement of the MUC1-C oncogenic protein in MCC progression.

92 ost differentially expressed and established oncogenic protein in PC, MUC4 regulation in terms of mic

93 Despite being the most frequently altered oncogenic protein in solid tumours, KRAS has historicall

94 membrane protein 1 (LMP-1) is the principal oncogenic protein in the EBV transformation process.

95 nity for nucleolin (NCL), a highly expressed oncogenic protein in various cancers.

96 anslocation in pro-B lymphocytes, encodes an oncogenic protein in which the E2A trans-activation doma

97 of astrocytoma have been designed to express oncogenic proteins in astrocytes, but have had limited s

98 of key mutational events in one of the most oncogenic proteins in cancer.

99 s and dysregulation of tumor suppressors and oncogenic proteins in cancer.

100 ion and conformational maturation of various oncogenic proteins in cancer.

101 ma and in TGFbeta-treated NK cells represses oncogenic proteins in neuroblastoma (MYCN and AURKA) and

102 is associated with assembly of numerous pro-oncogenic proteins in the plasma membrane and may play a

103 lation, thereby increasing the expression of oncogenic proteins including EGFR, IGF1R, CDK6 and PDGFR

104 HSR is critical for stabilizing oncogenic proteins including mutp53.

105 ocess is instrumental in the accumulation of oncogenic proteins, including AR, the molecular mechanis

106 on, TFIIIB is bound and activated by several oncogenic proteins, including c-Myc.

107 ion processing pathway that modifies several oncogenic proteins, including RAS.

108 beta-Catenin is an oncogenic protein involved in regulation of cell-cell ad

109 rent cancer types, causing the generation of oncogenic proteins involved in cancer hallmarks.

110 r environment by regulating the secretion of oncogenic proteins involved in diverse cellular processe

111 lational capacity, driving the production of oncogenic proteins involved in proliferation, evasion of

112 Expression of these known oncogenic proteins is enhanced on BCR activation and is

113 The subcellular localization of many oncogenic proteins is thought to be important for their

114 ted motility receptor (HMMR), a cell surface oncogenic protein, is widely up-regulated in human cance

115 r the correct folding and maturation of many oncogenic proteins, it has become a significant target f

116 The oncogenic protein kinase Aurora A is a critical regulato

117 Here, we present the cryoEM structure of the oncogenic protein kinase client BRAF(V600E) bound to HSP

118 r CDC37 in concert with HSP90 in maintaining oncogenic protein kinase clients and endorse the therape

119 BRAF(V600E) is the most frequent oncogenic protein kinase mutation known.

120 stimulate in vitro the activity of the proto-oncogenic protein kinase PKB/Akt, as has phosphatidylino

121 BRAF is an oncogenic protein kinase that drives cell growth and pro

122 gnaling network operating downstream of this oncogenic protein kinase to actively advance the surviva

123 itical activator of multiple prosurvival and oncogenic protein kinases and has garnered considerable

124 Several oncogenic protein kinases including c-raf-1 and pp60(v-s

125 nophilins can assemble steroid receptors and oncogenic protein kinases, such as v-Src and v-Raf, into

126 of clients, particularly activated or mutant oncogenic protein kinases.

127 ecular glues suppress the active form of the oncogenic protein KRAS.

128 g ribosome biogenesis and the translation of oncogenic proteins like MYC.

129 Translational regulation by oncogenic proteins may be a rapid and efficient mechanis

130 Apoptosis of oncogenic protein Mcl1-expressing cells is mainly regula

131 s been associated with the overexpression of oncogenic proteins (MUC1), multiple emerging reports hav

132 ll autonomous effects on the upregulation of oncogenic proteins, NFATc1 activation has non-cell auton

133 nhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acu

134 d steroid receptor coactivator 3 (SRC-3), an oncogenic protein overexpressed in multiple human cancer

135 rray (RPPA) was performed to assess multiple oncogenic protein pathways.

136 studies identify a novel role of PTPRF as an oncogenic protein phosphatase in supporting the activati

137 proaches have been widely used for degrading oncogenic proteins, providing a potentially promising th

138 eye-antennal discs, cooperation between the oncogenic protein Ras(V12) and loss-of-function mutation

139 onstrated induction of DR5 expression by the oncogenic proteins Ras and B-Raf and revealed the underl

140 cogenesis, as multiple tumor suppressors and oncogenic proteins regulate AKT signaling.

141 ACs) have recently been used to target these oncogenic proteins related to cell cycle progression.

142 ruly tumor-specific antigen that is also the oncogenic protein required for neoplasia.

143 entral events that leads to dysregulation of oncogenic protein Six1 in human cancers.

144 The oncogenic protein Ski associates with Smad proteins and

145 This renders the oncogenic protein SKP2 a promising therapeutic target.Se

146 ave been shown to engender dependence on the oncogenic protein Skp2 for survival of transformed cells

147 Here we show that both oncogenic proteins specifically downregulate the express

148 with, and is tyrosine-phosphorylated by, the oncogenic protein Src during mitosis.

149 trated an interaction between MUC1 and other oncogenic proteins such as beta-catenin, erbB receptors

150 y a variety of signaling proteins, including oncogenic proteins such as Ras and Rho GTPases.

151 We further demonstrate that oncogenic proteins such as STAT3 or BCL-X(L) are effecti

152 uppressors (such as ARID1B) and silencers of oncogenic proteins (such as RPS13).

153 HPV-encoded oncogenic proteins, such as E7, are promising tumor-spec

154 ing the N- and C-terminal regions of the JCV oncogenic protein, T antigen, in 11 of 23 samples and th

155 ection against carbonic anhydrase IX and the oncogenic protein targets BRD4(1) and MDM2.

156 The oncogenic protein Tax, encoded by human T-cell leukemia

157 ces and function as complexes with the viral oncogenic protein Tax.

158 HTLV-I encodes an oncogenic protein, Tax, which affects a variety of cellu

159 lt T-cell leukemia/lymphoma (ATLL) and viral oncogenic proteins, Tax and Hbz, are critical drivers of

160 Ski is an oncogenic protein that acts as a TGF-beta repressor and

161 Bcl-2 is an oncogenic protein that acts by inhibiting programmed cel

162 MUC1-C is an oncogenic protein that drives lineage plasticity in pros

163 binding protein 2 (IGFBP2) is a pleiotropic oncogenic protein that has both extracellular and intrac

164 d activator of transcription 3 (STAT3) is an oncogenic protein that is constitutively activated in nu

165 Previous roles for IRS1, an oncogenic protein that is essential for IGF-mediated pro

166 Survivin is an oncogenic protein that is highly expressed in breast can

167 nuclear chaperone nucleophosmin, a proposed oncogenic protein that is overexpressed in many differen

168 Thus, our results revealed NELFE as an oncogenic protein that may contribute to transcriptome i

169 r results demonstrate that HHV-8 vFLIP is an oncogenic protein that mimics the signaling activities o

170 s expressed in human cancer and generates an oncogenic protein that promotes tumorigenesis in gliobla

171 MDM2 is a key oncogenic protein that serves as a negative regulator of

172 gnant phenotype depends on oncogenic and non-oncogenic proteins that are essential to mediate oncogen

173 ate for cancers which depend on hyper-active oncogenic proteins that are regulated by the ubiquitin-p

174 Bcl2 and c-Myc are two major oncogenic proteins that can functionally promote DNA dam

175 Ras, MEK, PI3K, PTEN, and SHP2 are among the oncogenic proteins that can harbor mutations that encode

176 Bcl2 and c-Myc are two major oncogenic proteins that cooperatively promote tumor deve

177 al of exogenously applied miRNAs to suppress oncogenic proteins, the ERBB oncogene family was chosen

178 ristoylation of Src family kinases and other oncogenic proteins, thereby regulating their function.

179 lysis inhibitors to target the expression of oncogenic proteins through HuR degradation might foster

180 of EV secretion and increased expression of oncogenic proteins TMEM205, FAS, and STAT5 and downregul

181 ignificant increase in EV secretion carrying oncogenic proteins (TMEM205, STAT5, and FAS) in adipose

182 urther understand how c-Myc switches from an oncogenic protein to an apoptotic protein, we examined t

183 The ability of oncogenic proteins to regulate the rate of translation o

184 no acid substrates, leading to disruption of oncogenic protein translation, tumour differentiation an

185 In this study, we identified the oncogenic protein, TWIST1 (Twist), which is overexpresse

186 terstitial stroma through the release of the oncogenic protein tyrosine kinase (KIT)-containing exoso

187 in the transformation of epithelial cells by oncogenic protein tyrosine kinases.

188 stimuli, as well as in cells transformed by oncogenic protein tyrosine kinases.

189 Oncogenic protein tyrosine phosphatases have long been v

190 Bcr-Abl is the oncogenic protein-tyrosine kinase responsible for chroni

191 The signaling functions of the oncogenic protein-tyrosine kinase v-Ros were studied by

192 nificant role in cancer biology because many oncogenic proteins undergo prenylation.

193 The oncogenic protein Vav harbours a complex array of struct

194 n monocytic MDSCs and phosphorylation of pro-oncogenic proteins was associated with resistance to the

195 Due to its negative regulation of many oncogenic proteins, we hypothesized that GSK3beta may fu

196 (EBV) latent membrane protein 1 (LMP1) is an oncogenic protein which has previously been shown to eng

197 is, slowing proliferation, and degrading key oncogenic proteins without inducing a heat shock respons

198 tes the signaling pathways that regulate the oncogenic protein YAP1 and identifies a combination ther